Please assess the completion status of the following clinical trial:

Trial Title: Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria Stage 1 and 2:~* Documented community engagement from community leader and a signed inform consent form (ICF) from each participant must be available~* Participant Stage 1 must be 18 years or older at screening and be resident in selected study community with no intention to move from study area within the next 5 months~* Participant must be healthy with no abnormalities in laboratory screening tests within 28 days before Dose 1 vaccination~* Female participants of childbearing potential must use adequate birth control measures and must have a negative pregnancy test at screening and immediately prior to each study vaccination~* Participant must pass the test of understanding (TOU)~Additional Inclusion criteria Stage 2:~* One year or older at screening (children of enrolled parents are eligible)~* Parent/legal guardian (for children) must pass the TOU before signing the ICF~* Subjects aged 7 years and older will be asked to give positive assent in the presence of a witness~Exclusion Criteria:~* Diagnosed with EVD or under quarantine/exposed to Ebola or body temperature equal of \>= 38 degree Celsius (fever)~* Having an acute illness (mild in nature that can be treated at home) or any clinically significant acute/chronic medical condition or having a decreased number of red blood cells/hemoglobin in the blood (anemia)~* Previously participated in another Ebola interventional study or received any Ad26/MVA-based candidate vaccine~* Vaccinated with live attenuated vaccines within 30 days or with inactivated vaccines 15 days before Dose 1 vaccination~* Treated with an immunosuppressive drug at the time of screening~Additional exclusion criteria:~- Children up to 5 years of age with severe malnutrition (underweight or Z-score weight \<2)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stage 1: Active vaccination (Type: EXPERIMENTAL): Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
- Stage 2: Active vaccination (Type: EXPERIMENTAL): Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
- Stage 2: Active vaccination for children (Type: EXPERIMENTAL): Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
- Stage 2: Control vaccination (Type: ACTIVE_COMPARATOR): MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
- Stage 2: Control vaccination for children (Type: ACTIVE_COMPARATOR): MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.

Based on this trial design, predict the completion outcome and termination type (if applicable).